Press Release

Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting

by
Andrés Bratt Leal

Presentation of Data from Clinical Trial of Aspen’s Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson’s Disease SAN DIEGO, June 9, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. announced its participation in “Illuminating the Future,” the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in Hong Kong June 11-14. Aspen Co-founder and Senior Vice President, Research … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

by
Xiaokui Zhang, PhD

Presentation Covers Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease SAN DIEGO, May 14, 2025 /PRNewswire/ — Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held this week May 13-17, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The annual … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

by
step 234 edited

SAN DIEGO and NEW YORK, May 7, 2025 /PRNewswire/ — Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) therapy being studied in patients with moderate to advanced Parkinson’s Disease (PD). After recent publication in Parkinsonism and Related Disorders, detailed 6-month data on … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

by
Xiaokui Zhang, PhD

Presentations Cover Automated Manufacturing of Aspen’s Autologous iPSC-derived Neuron Replacement Therapy for Parkinson’s Disease SAN DIEGO and NEW ORLEANS, May 7, 2025 /PRNewswire/ — Aspen Neuroscience scientists, led by Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting, held this week May 7-10 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer

by
Dalen Meeter

CFO Further Positions Company for Growth and Continued Advancement of Clinical Programs SAN DIEGO, April 30, 2025 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial Officer (CFO). “We are excited to welcome Dalen to our executive team during this significant period of growth … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

by
image 7

Clinical Trial Assesses Safety and Tolerability of Escalating Doses of ANPD001 Autologous, Dopaminergic Neuronal Cell Replacement Therapy SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson’s Disease (PD). The Autologous-derived Study of a … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson’s Disease

by
step 234 edited

Company is scaling out production of ANPD001 investigational cell therapy SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego-based GMP facility. ANPD001, an investigational cell therapy program for treating people with Parkinson’s disease (PD), is currently being studied … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at UBS Global Healthcare Conference

by
Aspen Kameel Farag IMG 7524 Final e1727705111641

SAN DIEGO, Nov. 12, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer Kameel Farag will present company updates in a fireside chat today at 4:15 pm PT at the UBS Global Healthcare Conference in Rancho Palos Verdes, Calif., where he will detail Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. The UBS Global Conference is designed to … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Collaboration and License Agreement with Cell X Technologies

by
Untitled design 19

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — Aspen Neuroscience has entered into a collaboration and license agreement with Cell X Technologies to advance Aspen’s plans for automating the iPSC stage of its autologous manufacturing platform. Aspen will leverage its established bioinformatics-based platform, and will lead all discovery, preclinical, development and commercialization activities associated with the advancement of automated manufacturing for … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Endpoints News Honors Aspen Neuroscience Co-Founder Dr. Jeanne Loring in “20 Women Breaking New Ground”

by
Untitled design 17

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — EndPoints News has named Jeanne Loring, PhD, Aspen Neuroscience co-founder and senior advisor, a recipient of the 20 Women Breaking New Ground in BioPharma. The publication’s annual 2024 Women in BioPharma R&D Special Report recognizes the field’s most inspiring and driven women leaders. “Dr. Jeanne Loring is one of the earliest pioneers in human stem cell … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved